Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,150,000 shares, a growth of 8.6% from the April 15th total of 3,820,000 shares. Based on an average daily volume of 778,300 shares, the days-to-cover […]
Kezar Life Sciences (KZR) Buy Rating Reiterated at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Kezar Life Sciences (NASDAQ:KZR) Given Buy Rating at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the.